Vir Biotechnology, Inc. (NASDAQ: VIR) is a Healthcare company (Biotechnology) with a market capitalization of $1.6B. The Maz Rating grades it against the other companies in its sector.
Vir Biotechnology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.25, Vir Biotechnology, Inc. trades at 5.2x sales and 1.7x book value. Over the last twelve months it generated about $303M of revenue and a net loss of $214M. It runs a gross margin of 97.2%, an operating margin of -69.8% and a net margin of -61.0%. It shows return on equity of -21.4%, return on invested capital of -20.3% and a free cash flow yield of -9.0%. On the balance sheet: a debt-to-equity ratio of 0.10 and a current ratio of 6.30. Over the past 52 weeks the share price ranged from $5.32 to $14.38, with a beta of 1.70.
Vir Biotechnology, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 10 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Vir Biotechnology, Inc. (VIR) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global and Dow Jones, and fails AAOIFI, MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 49.0% / 30% · Interest income / Revenue -4959.04% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 24.9% / 33% · Receivables / Mkt Cap (36m) 0.47% / 49% · Interest income / Revenue -4959.04% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 24.9% / 33.33% · Receivables / Mkt Cap (24m) 0.47% / 33.33% · Interest income / Revenue -4959.04% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 4.44% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 44.1% / 33.33% · Receivables / Avg Assets (4Q) 0.78% / 33.33% · Interest income / Revenue -4959.04% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 41.2% / 33.33% · (Cash+Recv) / Total Assets 42.0% / 33.33% · Interest income / Revenue -4959.04% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Vir Biotechnology, Inc. (VIR) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global and Dow Jones, and fails AAOIFI, MSCI and FTSE.
No. Vir Biotechnology, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
Vir Biotechnology, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.